BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26351728)

  • 1. Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors.
    Kim MK; Shin H; Park KS; Kim H; Park J; Kim K; Nam J; Choo H; Chong Y
    J Med Chem; 2015 Sep; 58(18):7596-602. PubMed ID: 26351728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability.
    Kim H; Kim MK; Choo H; Chong Y
    Bioorg Med Chem Lett; 2016 Jul; 26(14):3213-3215. PubMed ID: 27261178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
    Norman P
    Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.
    Simov V; Deshmukh SV; Dinsmore CJ; Elwood F; Fernandez RB; Garcia Y; Gibeau C; Gunaydin H; Jung J; Katz JD; Kraybill B; Lapointe B; Patel SB; Siu T; Su H; Young JR
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1803-8. PubMed ID: 26927423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linear propargylic alcohol functionality attached to the indazole-7-carboxamide as a JAK1-specific linear probe group.
    Kim MK; Shin H; Cho SY; Chong Y
    Bioorg Med Chem; 2014 Feb; 22(3):1156-62. PubMed ID: 24398382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.
    Chrencik JE; Patny A; Leung IK; Korniski B; Emmons TL; Hall T; Weinberg RA; Gormley JA; Williams JM; Day JE; Hirsch JL; Kiefer JR; Leone JW; Fischer HD; Sommers CD; Huang HC; Jacobsen EJ; Tenbrink RE; Tomasselli AG; Benson TE
    J Mol Biol; 2010 Jul; 400(3):413-33. PubMed ID: 20478313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Amino-pyrrolopyridine-5-carboxamide: a novel scaffold for JAK1-selective inhibitors.
    Shin H; Kim MK; Chong Y
    Chem Pharm Bull (Tokyo); 2014; 62(3):217-20. PubMed ID: 24583775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.
    Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Liu Q; Batt D; Lombardo LJ; Vyas D; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Lippy J; Khan J; Sack JS; Purandare AV
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2809-12. PubMed ID: 25987372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
    Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
    Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
    Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
    J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.
    Williams NK; Bamert RS; Patel O; Wang C; Walden PM; Wilks AF; Fantino E; Rossjohn J; Lucet IS
    J Mol Biol; 2009 Mar; 387(1):219-32. PubMed ID: 19361440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Biological Evaluation of
    Park E; Lee SJ; Moon H; Park J; Jeon H; Hwang JS; Hwang H; Hong KB; Han SH; Choi S; Kang S
    J Med Chem; 2021 Jan; 64(2):958-979. PubMed ID: 33428419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of azabenzimidazoles as potent JAK1 selective inhibitors.
    Vasbinder MM; Alimzhanov M; Augustin M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Goodwin K; Huszar D; Kawatkar A; Kawatkar S; Read J; Shi J; Steinbacher S; Steuber H; Su Q; Toader D; Wang H; Woessner R; Wu A; Ye M; Zinda M
    Bioorg Med Chem Lett; 2016 Jan; 26(1):60-7. PubMed ID: 26614408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Janus kinases by tyrosine phosphorylation inhibitor, Tyrphostin AG-490.
    Rashid S; Bibi N; Parveen Z; Shafique S
    J Biomol Struct Dyn; 2015; 33(11):2368-79. PubMed ID: 26017266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.
    Zak M; Mendonca R; Balazs M; Barrett K; Bergeron P; Blair WS; Chang C; Deshmukh G; Devoss J; Dragovich PS; Eigenbrot C; Ghilardi N; Gibbons P; Gradl S; Hamman C; Hanan EJ; Harstad E; Hewitt PR; Hurley CA; Jin T; Johnson A; Johnson T; Kenny JR; Koehler MF; Bir Kohli P; Kulagowski JJ; Labadie S; Liao J; Liimatta M; Lin Z; Lupardus PJ; Maxey RJ; Murray JM; Pulk R; Rodriguez M; Savage S; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Xiao L; Xiao Y
    J Med Chem; 2012 Jul; 55(13):6176-93. PubMed ID: 22698084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
    Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.
    Soth M; Hermann JC; Yee C; Alam M; Barnett JW; Berry P; Browner MF; Frank K; Frauchiger S; Harris S; He Y; Hekmat-Nejad M; Hendricks T; Henningsen R; Hilgenkamp R; Ho H; Hoffman A; Hsu PY; Hu DQ; Itano A; Jaime-Figueroa S; Jahangir A; Jin S; Kuglstatter A; Kutach AK; Liao C; Lynch S; Menke J; Niu L; Patel V; Railkar A; Roy D; Shao A; Shaw D; Steiner S; Sun Y; Tan SL; Wang S; Vu MD
    J Med Chem; 2013 Jan; 56(1):345-56. PubMed ID: 23214979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease.
    Yang T; Cui X; Tang M; Qi W; Zhu Z; Shi M; Yang L; Pei H; Zhang W; Xie L; Xu Y; Yang Z; Chen L
    J Med Chem; 2022 Feb; 65(4):3151-3172. PubMed ID: 35113547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational analyses of JAK1 kinase domain: subtle changes in the catalytic cleft influence inhibitor specificity.
    Zhang X; Hu Y; Yuan Z
    Biochem Biophys Res Commun; 2008 May; 370(1):72-6. PubMed ID: 18346458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.